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Abstract
Schizophrenia (SCZ) is a complex mental disorder, with a longstanding history of 
neurobiological investigation. It is more common in those persons who are genetically 
predisposed to the disorder. Since Kraepelin, psychiatrists were aware that the SCZ 
tended to run in families. Its heritability is up to 85%. Although the etiology of SCZ 
is unknown, it is now thought to be multifactorial, with multiple susceptibility genes 
interacting with environmental and developmental factors. There is a huge amount of 
genetic studies, including polymorphisms, expression, methylation, microRNAs, and 
epigenomics. However, identifying genes for SCZ using traditional genetic approaches 
has thus far proven quite difficult. Reasons for this include the complexity, heterogeneity, 
and comorbidity of this disorder, and also the poor definition of the clinical phenotype. 
Important approaches to find the relation between genotype and phenotype and may 
be causal genetic factors are endophenotypes and pathway analysis. However, genetic 
researchers need to consider carefully the models of causality they choose. There is a 
pathophysiological pathway that extends from genes, through proteins, neurons, neural 
circuits, neural regions, mental functions, external behaviors, and symptoms of SCZ. In 
this chapter, the genetics and epigenetics of SCZ are briefly discussed.
Keywords: schizophrenia, genetic, epigenetic, etiology, pathophysiology, 
endophenotype, pathway analysis
1. Introduction
Schizophrenia is a serious, disabling, and complex mental disorder, with a longstanding 
history of neurobiological investigation [1]. It may be one of the most disabling disorders 
known to human. Schizophrenia can affect anyone at any point in his or her life. It is more 
common in those persons who are genetically predisposed to the disorder. The first psychotic 
episode generally occurs in late adolescence or early adulthood and often appears earlier in 
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men than in women. Schizophrenia, as a common disorder, has a worldwide prevalence of 
around 0.3–1.0% [2]. Clinically, it is characterized by a combination of positive and negative 
symptoms, cognitive impairments, and disorganized behaviors.
There are 130,024 citations (110,613 papers, 17,847 reviews, and 1564 meta-analysis) related to 
“schizophrenia,” 12,038 citations (9666 papers, 2134 reviews, and 238 meta-analysis) related to 
“schizophrenia gene,” 1317 citations (1060 papers, 178 reviews, and 79 meta-analysis) related 
to “schizophrenia genome-wide association study,” and 234 citations (216 papers, 11 reviews, 
and 7 meta-analysis) related to “schizophrenia gene enrichment” in PubMed (accessed on 
January 29, 2018).
Since Kraepelin delineated the disorder dementia praecox in 1899, psychiatrists were aware that 
the SCZ tended to run in families. Until now, there are several family studies in SCZ [3, 4]. While, 
the probability of developing SCZ in general population is 1%, the probability of its developing 
as the offspring of one parent with the disorder is approximately 17%, and the offspring of both 
parents with the disorder is approximately 46% [5].
A vulnerability-stress model, in which SCZ is thought to be multifactorial, with multiple sus-
ceptibility genes is interacting with environmental and developmental factors. For example, the 
immune response to a wide variety of bacterial or viral pathogens may be the link between pre-
natal infection and postnatal brain pathologies, including SCZ [6]. Additionally, intrauterine or 
postnatal complications with a negative impact on fetal brain development, nutritional deficien-
cies with effects on neurotransmitter systems, or maternal exposure to stressors are among the 
other important factors [7]. Identifying genes for psychiatric disorders using traditional genetic 
approaches has thus far proven quite difficult. Reasons for this include the complexity, heterogene-
ity, and comorbidity of these disorders and also the poor definition of the clinical phenotype [8]. 
Different studies, including MicroRNAs [9, 10], genetic polymorphisms [11, 12], gene expression 
[13, 14], methylation [15], and epigenomics [16, 17] are the most important genetic studies in SCZ.
2. Genetics of schizophrenia
2.1. An overview
Evidence including genetic findings shows that the early neurodevelopmental events have 
been implicated in the pathogenesis of disorder (Table 1) [1]. Traditionally, the most genetic 
researches on SCZ have concentrated on chromosomes and genes. These include cytogenetics, 
linkage, association, gene expression, and whole genome and exome scans. Although these 
studies have identified a number of genomic regions of interest, these have not produced any 
confirmed causations.
There are reasons as to why genetic approaches have met with little success in SCZ. First is that, 
there are no specific biological markers. Diagnostic systems, including diagnostic and statisti-
cal manuals of mental disorders (DSMs) and international classifications of diseases (ICDs), 
are categorical classifications and are based on interview and self-reporting of the patients. 
So, they are not optimal in genetic research on complex disorders. Second is the problem of 
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genotype-phenotype relationship. After a century ago, when Wilhelm Johannsen proposed 
the terms “genotype” and “phenotype,” our knowledge about the genetics, phenotype, and 
the concept of causality has evolved dramatically [18]. For example, genotype heterogeneity 
means that there are many genotypes that produce the same phenotype. In addition, pheno-
type heterogeneity means that the same genotype may produce different phenotypes. The 
alternate approach to find the relationship between genotype and phenotype may be endo-
phenotypes that will be useful in detecting genes contributing to SCZ [19, 20]. However, the 
studies of endophenotypes (characteristics that are intermediate between the genotype and a 
phenotype of interest) associated with SCZ are not yet enough. Another approach may be the 
path analysis to identify causal variables that produce phenotypes [21, 22]. However, the cho-
sen models of causality are very important [18]. Third is the genetic hypothesis being tested. 
The problems are the number of gene variants involved, the heterogeneous mechanism of 
the disorder, and the understanding of their interactions with the environmental and devel-
opmental factors to predisposition to SCZ. So, there is a long pathophysiological chain that 
extends from genes, through proteins, neurons, neural circuits, neural pools, neural regions, 
mental functions, external behaviors, and symptoms construct of SCZ.
By using high-throughput technologies, a huge amount of studies, including genome-wide 
association studies (GWASs) have reported that genetic variants, such as copy number 
variations (CNVs) or single nucleotide polymorphisms (SNPs) play significant roles in the 
pathogenesis of SCZ. In recent years, and based on the emergence of international consortia 
to achieve larger sample sizes, clinical, and statistically expertise and also replicable genetic 
findings [23], our understanding of the genetic architecture of SCZ, the number of risk variants, 
and their frequencies and effect sizes have been transformed. Genome-wide association studies 
of genetic variants have approximately tripled the number of candidate genetic loci [24]. The 
Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC) used GWAS 
arrays to identify 128 independent associations spanning 108 regions. These findings demon-
strate the involvement of biological processes of the brain. For example, there are associations 
among gene expression patterns in tissues with some roles in the immune system, providing 
support for the link between the immune system and SCZ [23].
Traditional 
structural genetic 
studies
Newer structural 
genetic studies
Traditional functional 
genetic studies (gene 
encoding studies)
Newer functional 
genetic studies
Epigenetic studies
Cytogenetic studies Genome-wide 
association studies 
(GWASs)
mRNA studies microRNA studies DNA modification 
studies
Linkage studies Whole exome studies Protein studies Long noncoding 
RNA studies
Histone modification 
studies
Candidate gene 
association studies
Other noncoding 
RNA studies
Genome-wide 
expression studies
Table 1. An overview to the genetic and epigenetic studies of schizophrenia.
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2.2. Heritability
The heritability is a statistic that estimates the degree of variation in a phenotypic trait or disorder 
in a population that is due to genetic variation between individuals [25]. Schizophrenia is highly 
heritable [26] and its genetic architecture is complex and heterogeneous. Its heritability has been 
estimated from 81% [26] up to 85% [27], showing a non-Mendelian inheritance pattern [28]. 
Reported concordance rate of SCZ in monozygotic twins is about 50%; from 41–65% [27, 29], 
while siblings and dizygotic twins show proband concordance rates as high as 28% [27]. The risk 
of the general population developing the SCZ is about 0.3–1.0% worldwide [2, 30].
Evidence shows the heritability of different aspects of SCZ, such as brain region volumes [31, 
32] and cognitive disabilities [33]. Thus, the combination of genetics and brain imaging (imag-
ing-genetics approach) will be a useful strategy to assess the effects of risk genetic variants on 
anatomical and functional connectivities [32]. For example, the heritability in subcortical and 
limbic volumes ranged from 0.45 in the right hippocampus to 0.84 in the left putamen [31]. 
General cognitive disabilities in SCZ have also genetic contributors. By using the genome-
wide complex-trait analysis (GCTA) approach, to estimate the total heritability captured by 
common DNA markers on genotyping arrays [34], it was shown that individuals at ultra-high 
risk for the disorder, relatives of the patients with SCZ spectrum disorders, and children with 
antecedents of SCZ may have cognitive impairments as well [33].
2.3. Candidate gene association studies
The candidate gene association study has been a major approach to discover the causative 
genetic factors of complex traits or disorders. Prior to the GWAS era, candidate studies were 
a major approach in SCZ genetics [35] and have been a pioneer in the field of genetic associa-
tion studies to identify risk genetic variants associated with a particular trait or disorder [36]. 
These studies, including case-control and family studies, directly test the effects of genetic 
variants, usually CNVs or SNPs of potentially contributing genes. The candidate gene studies 
are relatively cheap and quick to perform, but are limited by how much is known about the 
biology of the disorder being investigated [37]. With the advent of rapidly changing technol-
ogy, there has been an explosion of in silico tools available to researchers, giving them fast, 
efficient resources, and reliable strategies to find casual genetic variants for candidate study 
or GWAS [36]. Population stratification is also a major confounding factor for population-
based case-control association studies and can result in false positive associations [38]. This 
may be solved by considering a replication study using an independent and random cohort 
of test and control populations or through a family study. These approaches may reduce the 
chance of occurrence of a similar admixture showing similar patterns of variations [39]. Prior 
to the advances brought about by the Human Genome Project [40], the International HapMap 
Project [41], and then, 1000 Genomes Project [42], it was difficult and expensive to genotype 
a comprehensive list of genetic variants in a genomic region. Investigators thus tended to 
genotype a few genetic markers in a candidate gene selected based on prevailing theories of 
the etiopathology of SCZ or positional candidate genes from linkage or cytogenetic studies.
The more popular hypothesis, the common disease—common variant hypothesis suggests 
that SCZ is associated primarily with common genetic variants [43]. Based on this hypothesis, 
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most of the genetic association studies have focused on these variations in SCZ. This hypoth-
esis constitutes the rationale of GWASs, in which millions of variants, including SNPs were 
assessed in thousands of individuals [44, 45]. Copy number variations are sections of the 
genome that are repeated and the number of repeats in the genome varies between individu-
als [46]. Structural variations of DNA, such as CNVs, have contribution to normal genomic 
variability and to risk for human diseases [47]. Many studies have demonstrated that CNVs 
play important roles in susceptibility to SCZ [47–49].
The SZGene database (obtained 11/2017) listed 1727 candidate gene papers investigating 
over 1008 genes and 8788 polymorphisms. Based on published genetic association studies of 
SCZ, it has been reported that across 118 meta-analyses, 16 genes, including APOE, COMT, 
DAO, DRD1, DRD2, DRD4, DTNBP1, GABRB2, GRIN2B, HP, IL1B, MTHFR, PLXNA2, 
SLC6A4, TP53, and TPH1 showed significant effects [50]. By using a translational conver-
gent functional genomics approach, using candidate genetic studies, and a poly evidence 
scoring and pathway analyses, many genes, including DISC1, TCF4, MBP, MOBP, NCAM1, 
NRCAM, NDUFV2, RAB18, ADCYAP1, BDNF, CNR1, COMT, DRD2, DTNBP1, GAD1, 
GRIA1, GRIN2B, HTR2A, NRG1, RELN, SNAP-25, TNIK, and a few top genes, including 
DISC1, HSPA1B, MBP, and TCF4 were identified [51]. Across meta-analyses, candidate genes, 
inclu ding APOE, COMT, DAO, DRD1, DRD2, DRD4, DTNBP1, GABRB2, GRIN2B, HP, IL1B, 
MTHFR, PLXNA2, SLC6A4, TP53, TPH1, RELN, MnSOD, GSTM1, ZNF804A, CACNA1C, AN 
K3, BDNF, GRIN3A, FAAH, DNMT1, MYO18B, CFB, GRM7, GRM8, miR-137, MPC2, and 
CSMD1 showed nominally significant effects [11, 50, 52]. However, some of them have been 
questioned [35, 53–55]. A likely reason why candidate gene studies did not achieve their pri-
mary aims is inadequate statistical power. However, the considerable efforts embodied in early 
studies unquestionably set the stage for current successes in genomic approaches to SCZ [35].
2.4. Genome-wide association studies
A GWAS or whole genome association study (WGAS) is an approach that involves rapidly scan-
ning genetic variants across the genomes of many people to find variations associated with a 
particular trait or disease. By using this approach, researchers can use the information to develop 
better hypotheses to detect, treat, and prevent the diseases. Such studies are particularly useful 
in finding genetic variations that contribute to mental disorders. Genome-wide association study 
searches the genome for a genome-wide set of genetic variants in different individuals to see if 
any variant is associated with a normal trait or a disease. This is a hypothesis-free strategy, and 
typically searches the genome for SNPs, or CNVs that occur more frequently in people with a 
particular disease than in people without the disease. Genome-wide significance is P < 5.0 × 10(−8). 
Meta-analyses of GWAS data have begun to lead to promising new discoveries for SCZ [56]. 
Within the last few years, large-scale GWASs of SCZ have identified multiple risk variants with 
significant association with the disorder. However, these variants could explain only a small 
proportion of the heritability of SCZ and their effect sizes are relatively small, suggesting that 
more risk variants may be detected when increasing sample size in analysis [57, 58].
By the analysis of an European ancestry sample GWAS and then through a replication study, 
Ripke et al. [45] found significant associations for seven loci, including 1p21.3, 2q32.3, 6p21.32-
p22.1, 8p23.2, 8q21.3, 10q24.32-q24.33, and 18q21.2 with SCZ. The strongest finding was with a 
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miRNA-137 SNP, a known regulator of neuronal development. In a meta-analysis of 18 GWASs 
and a replication study, Aberg et al. [3] found significant effect with SCZ for TCF4, NOTCH4, 
POM121L2, AS3MT, CNNM2, and NT5C2 genes. By carrying out a GWAS meta-analysis, 
Sleiman et al. [59] found 40 SNPs in six significant loci, including SDCCAG8, ITIH1, major his-
tocompatibility complex (MHC), MAD1L1, CSMD1, and TSNARE1 genes. By analyzing two 
genome-wide association data sets of European-American patients with SCZ, significant asso-
ciations between negative symptoms of SCZ and BCL9, TMEM245, RNF144B, CTNNA3, and 
ZNF385D genes have been detected [60]. The largest published GWAS meta-analysis of SCZ is 
of 34,000 patients in a meta-analysis of 52 GWASs from the Psychiatric Genomics Consortium 
(PGC) which identified 108 genome-wide significant loci [61]. Through large GWAS, an intronic 
SNP within CSMD1 gene, rs10503253, one of the top risk SNPs for SCZ in Europeans discov-
ered [11]. It may be concluded that the risk “A” allele is relevant to brain structure and neuro-
cognitive functioning and these effects may be a part of the mechanism by which the CSMD1 
mediates risk for SCZ [62, 63]. By combining two SCZ cohort studies, Luo et al. [58] reported a 
genome-wide significant risk locus at 22q13.1. In their meta-analysis, seven SNPs on chromo-
some 22q13.1 reached the genome-wide significant effect, and most significant association was 
with SNP rs6001946 (P = 2.04 × 10[−8]). All seven SNPs are located in the MKL1 gene.
It has been reported that a rare risk variation at AKAP9 and a protective variation at NRXN1 
are in susceptibility to SCZ [64]. By doing a meta-analysis of data from the PGC and additional 
SCZ family sample, SNP rs4765905 in CACNA1C showed a strong effect [65]. Through the 
meta-analysis of a UK case/control study and GWAS data from the PGC, a significant effect 
of two SLC30A3 gene SNPs (rs11126936 and rs11126929) was found in female subjects [66]. 
Chang et al. [67] in a GWAS study in Europeans (but not in Asians) found a significant effect 
with SCZ for VRK2 gene SNP rs2312147. In their GWAS meta-analysis, it has been reported that 
rs10489202 in MPC2 gene is significantly associated with SCZ in Han Chinese samples [68].
2.5. Gene expression studies
2.5.1. Gene encoding studies
It has been postulated that the underlying neuropathology of SCZ, at least, resides in the peri-
odic activation of a defective genes, as a progressive process [69]. Changes in gene expression 
in brains of patients with SCZ have been hypothesized to reflect possible pathways related 
to its pathophysiology [70]. Progressive cortical reorganization and gray matter abnormali-
ties may be pathophysiological processes in disorder [71, 72]. These changes are in parallel 
with changes in symptoms and cognitive impairments [73]. Epidemiological evidence sug-
gests the widespread gene-environment interactions in the etiology of SCZ [74, 75]. So, it may 
be hypothesized that these interactions can alter the gene expression pattern in the brain of 
patients. By using the Gene Expression Omnibus Database, Karim et al. [76] showed a total of 
527 differentially expressed genes of which 314 are up regulated and 213 are down regulated.
There are differences in pathophysiology of SCZ between male and female patients. It seems 
that the pattern of genetic architecture is different between two sexes. For example, the upregu-
lation of 59 genes and downregulation of other 105 genes in the peripheral blood mononuclear 
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cells (PBMCs) from patients with SCZ have been reported [77]. By using the PBMC samples, 
a genome-wide expression analysis showed the alterations of gene expressions, such as 
MEF2D, S100A12, and AKT1, with immune system function [77, 78]. Additionally, in their 
meta-analysis, Qin et al. [13] tested for a sex by diagnosis interaction on gene expression. 
These authors reported that 23 genes were up regulated and 23 genes were down regulated 
significantly in the male group. Several of these genes, including ATP5B, ATP5A1, MRPL23, 
AFG3L2, and ABCG2, are related to energy metabolism. Four genes, including BEX1, UBL4A, 
CD99, and MID1, were located on sex chromosome [13]. By using a large European-wide 
sample in their meta-analysis, Perez-Becerril et al. [66] found the risk alleles of two SLC30A3 
variants in females, which were associated with gene expression. In a meta-analysis of 41 
studies, it has been shown a significant increase in expression of pro-inflammatory genes, 
including IL-1β, IL-6, and TNF-α on transcript and protein levels in patients with SCZ [79].
2.5.2. Micro-ribonucleic acids (miRNAs) studies
These RNAs are small noncoding RNA molecules which exert their functions by pairing with 
messenger RNAs (mRNAs) [80] and are powerful negative regulators of gene expression [81, 
82]. They function in cell proliferation and death, patterning of the nervous system, and also as 
modulators of target mRNA translation and stability [83], RNA silencing and post-transcrip-
tional regulation of gene expression [84]. There are different sets of miRNAs expressed in differ-
ent cell types and tissues [85] and in many other biological processes, such as insulin secretion, 
B-cell development [86], hematopoiesis [87], and metabolic biochemistry [81]. Aberrant miRNA 
expression is implicated in many disorders, such as cancers [88], ischemic heart diseases [82], 
and mental disorders as well. A huge amount of evidence implicates miRNAs as a class of 
modulator for human tumor initiation and progression [80]. However, miRNA-based therapies 
are under investigation. In a meta-analysis, Ma et al. [9] reported that miR-137 genetic vari-
ant rs1625579 is significantly associated with SCZ. Additionally, in another meta-analysis of 52 
GWASs completed in 2014, Hauberg et al. [10] showed that the SCZ risk genes were regulated 
by miRNAs (P < 2 × 10[−16]). The strongest miRNAs were miR-9-5p, miR485-5p, and miR-137 [9].
2.5.3. Transcriptome and proteome studies
Transcriptome is the set of all RNA molecules (transcripts) in one cell, a population of cells 
or in a given organism. The study of transcriptome examines the expression level of RNAs 
in a given cell population, often focusing on mRNA, but sometimes including others such as 
transfer RNAs (tRNAs) and soluble RNAs (sRNAs).
The proteome is the entire set of proteins expressed by a genome in a cell, tissue, or organ-
ism at a certain time, under defined conditions. Proteomics is the study of the proteome. 
Understanding of the implication of genetic variations in mental disorders requires transla-
tion into functional effects [70]. New technologies allow the investigation of levels of mRNAs 
and proteins at the same time [89].
A significant increased expression of SLC2A3—glucose transporter, and DAAM2—actin 
assembly factor, and a significant decreased expression of OMA1—zinc metallopeptidase, 
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NLN1, and MYBPC3—myosin C have been reported in the first onset of SCZ [90]. The periph-
eral mRNA of these genes may be potential biomarkers in early stages of disorder course [89].
3. Epigenetics of schizophrenia
3.1. Epigenetics and epigenetics code
The Greek prefix epi- (“over”) in epigenetics implies features that are “on top of” or “in 
addition to” the traditional genetic basis for inheritance (Table 1). Epigenetics is the study 
of changes in gene functions, including gene expression that are heritable and that does not 
entail a change in DNA sequence [91]. Examples of epigenetic mechanisms are DNA methyla-
tion and acetylation and also histone modifications. The epigenetic changes are potentially 
reversible. Epigenetic codes are heritable DNA/histone modifications that specify patterns of 
gene expression through differentiation and development [92].
3.2. Epigenetic study of schizophrenia
Epigenotyping might be integrated along with genotyping and phenotyping as means of 
implementing advanced precision medicine [93]. Epigenetic mechanisms regulate the key 
neurobiological and cognitive processes in the brain [94]. Epigenetic drugs, such as histone 
de-acetylation, and DNA methylation inhibitors have received increased attention for the 
management of mental disorders [95].
Neuroepigenomics represents an effort to unify the research available on the molecular pathol-
ogy of mental disorders, such as single DNA methylation, to epigenome-wide association stud-
ies, post-translational modifications of histones, or nucleosomal positioning [96]. A huge amount 
of studies examining the role of epigenome, including epigenetic signaling, such as DNA and 
histone modifications in the etiology of SCZ was published [97, 98]. Large-scale consortia, such 
as the PGC and the Common Minds Consortium provide detailed insight into the epigenetic risk 
architectures of SCZ [99]. However, the absence of consistently replicated genetic effects together 
with changes in gene expression suggests the role of epigenetic mechanisms in SCZ [16].
Brain development is guided by interactions between the genome and environment, such as 
early life adversity. Epigenetic mechanisms can mediate these interactions and increase the 
risk of SCZ [17]. In a mixed model of SCZ risk, abnormal epigenetic states with large effects 
are superimposed on a polygenic liability to SCZ [100]. It has been reported that several 
genes related to nucleosome and histone structure are dysregulated in PBMC of patients with 
SCZ. It may be suggesting a potential epigenetic mechanism underlying the risk factor for the 
development of SCZ [101].
Genome-scale mapping of epigenetic mechanisms, including chromosomal loopings, and other 
epigenetic determinants of genome organization help to understand the mechanisms contribut-
ing to dysregulated expression of synaptic and metabolic genes in SCZ [102]. Some authors have 
found methylation differences in different genes, including COMT, RELN, and in some other 
genes implicated in dopaminergic, serotoninergic, γ-aminobutyric acid (GABA)ergic, and gluta-
matergic pathways [103]. It has been proposed that prenatal stress induces neurodevelopmental 
Psychotic Disorders - An Update88
alterations in the prefrontal cortex that are expressed as cognitive impairments observed in 
SCZ [104]. Reelin (RELN) is involved in cortical neural connectivity and synaptic plasticity. 
Downregulation of RELN expression due to its hypermethylation has been associated with epi-
genetic changes in this gene of the prefrontal cortex of patients with SCZ [97].
A significant portion of patients with SCZ shows deficits in glutamate decarboxylase 1 
(GAD1). This gene encodes a 67 kDa glutamate decarboxylase (GAD67) protein in multiple 
areas of adult cerebral cortex. This event, possibly reflecting molecular defects in subtypes 
of GABAergic interneurons essential for network synchronization and cognition [105]. 
Dysfunction of prefrontal cortex in SCZ includes the changes in GABAergic mRNAs, includ-
ing decreased expression of GAD1. It has been demonstrated that the methylation frequency 
at CpG dinucleotides located at the proximal GAD1 promoter shows a significant deficit in 
repressive DNA methylation in patients with SCZ [106]. Adverse life events have been found 
to control DNA methylation in postmitotic neurons. This phenotype in SCZ was accompanied 
by a persistent increase in AVP gene expression [107].
4. Pathway analysis
4.1. An overview
The concept of pathway is more complex structure than a cluster. Pathways in biology cor-
respond to series of interactions among different molecules in a cell that lead to a certain 
product. Pathway-based analysis provides a technique, which allows a comprehensive under-
standing of the molecular mechanisms underlying complex traits or disorders, such as mental 
disorders. There are a variety of pathway-based approaches, including SNP/GWAS-derived 
pathway analysis, which correspond to different research designs and data types [108].
In pathway analysis, data come from high throughput biology. Gene sets corresponding to 
biological pathways are tested for significant relationships with a phenotype. Genotyping, 
gene expression arrays, or any data elements that could be mapped to genes or gene products 
could be used. It may be concluded that the pathway analysis represents a potentially pow-
erful and biologically-oriented bridge between genotypes and phenotypes [109]. Pathway 
analysis has become the first choice for gaining insight into the underlying biology of differ-
entially expressed genes and proteins, as it reduces complexity and has increased explanatory 
power [110].
4.2. Pathway analysis in schizophrenia
By using the key words of “genome-wide association study” in PubMed database, over 22,000 
human GWAS publications have described genetic associations to a wide range of disorders 
and traits. Additionally, by using the key words of “genome-wide association study and schizo-
phrenia” in PubMed, more than 1190 human GWAS publications have described genetic asso-
ciations to SCZ. Genome-wide data sets are increasingly viewed as foundations for discovering 
pathways and networks relevant to phenotypes [111]. However, extending GWAS findings to 
mechanistic hypotheses about the development of SCZ has been a major ongoing challenge.
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Sundararajan et al. [22] have been used the clinically relevant and reported susceptibility 
genes associated with SCZ and available gene analysis program, and created a molecular 
profile of the updated SCZ genes. These genes were predominantly expressed in specific 
brain regions, including the cerebellum, cerebral cortex, medulla oblongata, thalamus, and 
hypothalamus. Interestingly, by the analysis of major biological pathways and mechanisms 
associated with SCZ genes, these authors identified glutaminergic, serotonergic, GABAergic, 
and dopaminergic receptors, calcium-related channels, solute transporters, and neurode-
velopmental genes. Biological mechanisms, including synaptic transmission, membrane 
potential, and transmembrane ion transport regulation were identified as leading molecular 
functions associated with SCZ genes [22].
Regarding the involvement of neuroinflammation in pathogenesis of SCZ in postmortem 
brains of patients with SCZ, neuroinflammatory markers and an overall increase in expres-
sion of pro-inflammatory genes have been reported [79].
By using a translational convergent functional genomics approach and a poly evidence scor-
ing and pathway analyses, Ayalew et al. [51] identified top genes (e.g., DISC1, HSPA1B, MBP, 
and TCF4), brain development, myelination, cell adhesion, glutamate receptor signaling, 
G-protein coupled receptor signaling, and cAMP-mediated signaling as key to pathophysiol-
ogy and as targets for therapeutic intervention.
Karim et al. [76] carried out pathway and gene ontology analyses and observed alteration in a 
few signaling pathways in neurons. These pathways were GABA receptor, immune response, 
G beta gamma, dopamine and cyclic AMP, complement system, axonal guidance, dendritic 
cell maturation, CREB, and interleukin-1 signaling pathways and networks.
By using the network-based approach for evaluating gene co-expression, Mistry et al. [112] 
found separate gene co-expression networks. Functional enrichment analysis showed that 
altered genes expression in SCZ associate with biological processes such as oxidative phos-
phorylation, myelination, synaptic transmission, and immune function [112].
Differentially expressed genes in PBMC of patients with SCZ have been reported that were 
involved in pathways such as cell adhesion, neuronal guidance, neurotrophins, oxidative 
stress, glucose metabolism, apoptosis, and cell-cycle regulation [78].
It has been suggested that the genetic basis of SCZ has a complex evolutionary history. It 
has been hypothesized that the genetic architecture components of SCZ are attributable to 
human lineage-specific evolution [113]. It has been shown that the SCZ genes are located near 
previously identified human accelerated regions (HARs). Additionally, these genes enrich in 
a GABA-related co-expression module significantly. These genes are differentially regulated 
in patients with SCZ. It has been concluded that genes located near the HARs are associated 
with important functional roles in the genetic architecture of SCZ [113].
Cell death is an active process that maintains tissue homeostasis. Three types of distinct cell 
death are apoptosis, autophagic cell death, and necrosis [114]. The apoptotic pathway will 
begin with death receptor activation. This activation leads to the formation of death receptor 
signaling pathways, resulting in the demolition of the cell [115]. It has been hypothesized that 
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an increase in apoptosis may underlie neuropathology of SCZ [116]. There are significant 
expression changes in death genes receptor signaling pathways in the dorsolateral prefrontal 
cortex of patients with SCZ, including the TNFSF13 and TNFSF13. It has been concluded that 
the increased TNFSF13 expression may be one of the abnormalities that contribute to the 
brain pathology in SCZ [116].
By using the factor analysis of symptoms of narrowly defined patients with SCZ through the 
clinician-rated operational criteria checklist items in an Irish family sample, implemented 
genome-wide association, gene-based, and gene-pathway analyses of these SCZ-based symp-
tom factors, Docherty et al. [117] could find three factors, including: a manic, a depressive, 
and a positive symptom factor. Gene-based analysis of these factors showed PTPRG and 
WBP1L genes. These genes were also implicated by the PGC study of SCZ [45]. It has been 
suggested that variants in these two genes might also act as modifiers of SCZ symptoms. 
Gene pathway analysis of the mania factor indicated over-representation of glutamatergic 
transmission, GABA-A receptor, and cyclic GMP pathways and these pathways may have 
differential influence on affective symptoms in SCZ [117].
Through the interrogating SCZ genes and their complex interactions at various levels, includ-
ing transcripts and proteins and also environmental and developmental factors, our knowl-
edge and insight into the disorder processes will increase. This may possibly open the new 
avenues for more effective therapeutic interventions.
5. Future perspective
Although a huge amount of studies has been performed and significant progress has been 
made in past decades, the high heritability, phenotype heterogeneity, and strong genetic and 
epigenetic heterogeneity of SCZ still post as major challenges to the genetic dissection of this 
complex syndrome. Therefore, more studies are needed to explain its missing heritability 
[118]. It is essential to shift paradigm in understanding the etiopathology of SCZ. A critical 
question is “What is schizophrenia?” Is it a specific disorder or a heterogeneous syndrome? 
Changes in brain gene expression of the patients with SCZ may reflect the possible pathways 
related to pathophysiology of the syndrome.
A few suggestions for the next decade are studying the multiple brain regions in normal 
people to better understand neural circuitry, genetics and epigenetic patterns of the brain, 
peripheral biomarker studies, and analyze the other omics data, such as transcriptomics 
across a developmental series of brains. System biology and computational approaches will 
be useful to advance from normal brains to a more reliable and valid definition of the SCZ 
interactome and connectome [70].
Through the better understanding of pathophysiology of SCZ, at the levels of genetic and 
epigenetic, we could identify new leads for the management of this complex syndrome. 
However, which gene(s) is causal, how the risk genetic or epigenetic factors alter gene expres-
sion, and how they fit into pathology and syndrome pathways [119]. New drugs for SCZ are 
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essential needs for the patients. These drugs have to target pathophysiological alterations that 
are specific to syndrome. Schizophrenia is a multifactorial and strongly biologically heteroge-
neous syndrome. Identification of homogenous subgroups is increasingly necessary for new 
drugs discovery [120]. So, the above mentioned assays will help the researchers to understand 
the pathological processes and the development of better treatments [15, 119].
In addition to different approaches to the analysis for genes associated with SCZ, the genetics and 
epigenetic of specific psychopathology, including cognitive impairments, negative signs, disor-
ganized behaviors, etc., need to be addressed. In this regard, neuroimaging genetics approach 
will be useful. In addition, a psychiatric translational and phenomics approach (genome to mind 
phenome), understanding the pathology of syndrome in different levels, such as genetics, epi-
genetic, proteomics, and other omics data, and also neural circuit abnormalities, and endopheno-
types related to psychopathology and clinical phenotypes are another essential steps.
6. Conclusion
Schizophrenia is a complex, heterogeneous, and multifactorial syndrome. It has many levels, 
including genomics, epigenomics, transcriptomics, proteomics, metabolomics, neural circuit, 
endophenotype, and albeit clinical presentations. It seems that an ideal “multi-level diagnos-
tic system” has to include all of these levels to make a bioprofile. By doing this in the near 
future, we hope to have a more reliable and valid diagnostic system, better approach to its 
treatment and also prevention of mental disorders, including SCZ.
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